# Comprehensive profiling of CRISPR/dCas9 epigenome editors indicates a complex link between on and off target effects

**Authors:** Majid Pahlevan Kakhki, Fatemeh Rangani, Ewoud Ewing, Chiara Starvaggi Cucuzza, Galina Zheleznyakova, Maria Kalomoiri, Lea Kenny, Anika Raghavan, Chandana Rao Prakash, Gabe van den Hoeven, Tejaswi Venkata S. Badam, Ruxandra Covacu, Ioanna Andreou, Maria Needhamsen, Lara Kular, Maja Jagodic

PMC · DOI: 10.1186/s13059-026-03967-6 · 2026-01-31

## TL;DR

This study compares different CRISPR/dCas9 tools for DNA methylation editing and finds that while some are more effective, they also cause unintended changes in gene activity.

## Contribution

The study reveals that multimerization of DNA methyltransferase 3A increases editing potency but introduces widespread methylation and transcriptional changes.

## Key findings

- Multimerization of DNA methyltransferase 3A enhances editing potency but causes early methylation at promoter regions.
- Non-targeting gRNAs induce long-lasting methylation-independent transcriptional changes in RNA and energy metabolism genes.
- CRISPRoff shows fewer and less stable off-target effects but still causes transcriptome alterations.

## Abstract

CRISPR/dCas9-based epigenome editing systems, including DNA methylation epimodifiers, have greatly advanced molecular functional studies, revolutionizing their precision and applicability. Despite their promise, challenges such as the magnitude and stability of the on-target editing and unwanted off-target effects underscore the need for improved tool characterization and design.

We systematically compare specific targeting and genome-wide off-target effects of available and novel dCas9-based DNA methylation editing tools over time. We demonstrate that multimerization of the catalytic domain of DNA methyltransferase 3A enhances editing potency but also induces widespread, early methylation deposition at low-to-medium methylated promoter-related regions with specific gRNAs and also with non-targeting gRNAs. A small fraction of the methylation changes associated with transcriptional dysregulation and mapped predominantly to bivalent chromatin associating both with transcriptional repression and activation. Additionally, specific non-targeting control gRNAs cause pervasive and long-lasting methylation-independent transcriptional alterations particularly in genes linked to RNA and energy metabolism. CRISPRoff emerges as the most efficient tool for stable promoter targeting, with fewer and less stable off-target effects compared to other epimodifiers but with persistent transcriptome alterations.

Our findings highlight the delicate balance between potency and specificity of epigenome editing and provide critical insights into the design and application of future tools to improve their precision and minimize unintended consequences.

The online version contains supplementary material available at 10.1186/s13059-026-03967-6.

## Full-text entities

- **Genes:** Cas9 [NCBI Gene 46806597], EEF1A2 (eukaryotic translation elongation factor 1 alpha 2) [NCBI Gene 1917] {aka DEE33, EEF1AL, EF-1-alpha-2, EF1A, EIEE33, HS1}, BACH2 (BACH transcriptional regulator 2) [NCBI Gene 60468] {aka BTBD25, IMD60}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, STAT4 (signal transducer and activator of transcription 4) [NCBI Gene 6775] {aka DPMC, SLEB11}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, HPRT1 (hypoxanthine phosphoribosyltransferase 1) [NCBI Gene 3251] {aka HGPRT, HPRT}, CBX5 (chromobox 5) [NCBI Gene 23468] {aka HEL25, HP1, HP1A, HP1alpha}, TRIM28 (tripartite motif containing 28) [NCBI Gene 10155] {aka KAP1, PPP1R157, RNF96, TF1B, TIF1B, TIF1beta}, UBC (ubiquitin C) [NCBI Gene 7316] {aka HMG20}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668] {aka ATF, ATF1, ATF2, HFB1-GDNF, HSCR3}, TET1 (tet methylcytosine dioxygenase 1) [NCBI Gene 80312] {aka CXXC6, LCX, bA119F7.1}, DNMT3A (DNA methyltransferase 3 alpha) [NCBI Gene 1788] {aka DNMT3A2, HESJAS, M.HsaIIIA, TBRS}, MAF (MAF bZIP transcription factor) [NCBI Gene 4094] {aka AYGRP, CCA4, CTRCT21, c-MAF}, IRF4 (interferon regulatory factor 4) [NCBI Gene 3662] {aka IMD131, LSIRF, MUM1, NF-EM5, SHEP8}, IL6ST (interleukin 6 cytokine family signal transducer) [NCBI Gene 3572] {aka CD130, CDW130, GP130, HIES4, HIES4A, HIES4B}, PAX5 (paired box 5) [NCBI Gene 5079] {aka ALL3, BSAP, PAX-5}, Igh-V7183 (immunoglobulin heavy chain (V7183 family)) [NCBI Gene 16059] {aka B9-scFv, IgG, IgH, IgVH1(VSG), VH7183, VI24H}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, PRF1 (perforin 1) [NCBI Gene 5551] {aka HPLH2, P1, PFP}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, TBX21 (T-box transcription factor 21) [NCBI Gene 30009] {aka IMD88, T-PET, T-bet, TBET, TBLYM}, CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, MEIS1 (Meis homeobox 1) [NCBI Gene 4211], CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, DNMT3L (DNA methyltransferase 3 like) [NCBI Gene 29947], Lmnb1 (lamin B1) [NCBI Gene 16906], RNF112 (ring finger protein 112) [NCBI Gene 7732] {aka BFP, ZNF179}, DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}, PRDM1 (PR/SET domain 1) [NCBI Gene 639] {aka BLIMP-1, BLIMP1, PRDI-BF1}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}
- **Diseases:** NTC (MESH:D012327), Cancer (MESH:D009369), AML (MESH:D015470), mycoplasma (MESH:D009175), cytotoxicity (MESH:D064420), Neurological Disabilities (MESH:D009069), MS (MESH:D009103)
- **Chemicals:** doxycycline (MESH:D004318), streptomycin (MESH:D013307), uracil (MESH:D014498), sodium-bisulfite (MESH:C009279), TBS (MESH:D013725), cytosine (MESH:D003596), H2O (MESH:D014867), DTT (MESH:D004229), Dox (MESH:D004317), penicillin (MESH:D010406), H2O2 (MESH:D006861), Cocktail (-), Lipofectamine (MESH:C086724), ATP (MESH:D000255), CO2 (MESH:D002245), Luciferin (MESH:D000090562), L-glutamine (MESH:D005973), Reactive oxygen species (MESH:D017382), Tween (MESH:D011136), bisulfite (MESH:C042345), PVDF (MESH:C024865)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Mus musculus (house mouse, species) [taxon 10090], Streptococcus pyogenes (species) [taxon 1314], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** C for 5-10, T2A, Q147L, R882H
- **Cell lines:** HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), dCas9-3A3L — Mus musculus (Mouse), Mouse adrenal gland pheochromocytoma, Cancer cell line (CVCL_8479), d3A — Mus musculus (Mouse), Hybridoma (CVCL_C4Y6), dCas9-3A — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_VR73), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), dCas9 — Homo sapiens (Human), Embryonic stem cell (CVCL_C6TU)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12924462/full.md

---
Source: https://tomesphere.com/paper/PMC12924462